Anti-Mouse CD8 beta Antibody (53-5.8)
Based on 1 Customer Validation
Anti-Mouse CD8 beta Antibody (53-5.8) is an anti-mouse CD8 beta IgG2a monoclonal antibody. Anti-Mouse CD8 beta Antibody (53-5.8) can deplete CD8+ T cells and enhance cytotoxicity. Anti-Mouse CD8 beta Antibody (53-5.8) can be used for research on immunology.
For research use only. We do not sell to patients.
- Purity: 97.95%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Rat IgG1 kappa
Mouse
CD8 beta
Anti-Mouse CD8 beta Antibody (53-5.8) (0.1-10 μg/mL, 1-2 h) enhances cytotoxicity at low concentrations (0.1 μg/mL) and significantly inhibits killing function at high concentrations (> 1 μg/mL) in OT1 CD8+ T cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Anti-Mouse CD8 beta Antibody (53-5.8) (500 μg, i.p., single dose, on the second day after injecting CD45.1+ OT1 T cells) exhausts CD8+ T cells and changes them to short lived effector cells (SLEC) phenotype with enhanced cytotoxicity in C57BL/6 mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SCID-beige mice (1 month) induced with Doxycycline (HY-N0565) diet (200 mg/kg)[1]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection (i.p.), once weekly after the end of treatment
-
Result:Decreased the number of CD8+ T cells.
Significantly increased the tumor recurrence rate compared to the control group.
-
Animal Model:C57BL/6 mice (5-10 weeks)[2]
-
Dosage:500 μg
-
Administration:Intraperitoneal injection (i.p.), single dose, on the second day after injecting CD45.1+ OT1 T cells.
-
Result:Caused CD8+ T cells to exhibit the SLEC phenotype with enhanced cytotoxicity.
P10300
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
in vivo CD8+ T cell depletion; in vitro CD8 blockade; Immunofluorescence
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse CD8 beta Antibody (53-5.8)]
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Tsao LC, et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nat Commun. 2025 Apr 2;16(1):3167. [Content Brief]
[2]. Cross EW, et al. Anti-CD8 monoclonal antibody-mediated depletion alters the phenotype and behavior of surviving CD8+ T cells. PLoS One. 2019 Feb 8;14(2):e0211446. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse CD8 beta Antibody (53-5.8) Related Classifications
HY-P99128 Related Classifications
Powered by Bioz